Intravenous Immunoglobulin Therapy in Paraneoplastic Neurological Syndromes

Overview

Journal J Neurol

Specialty Neurology

Date 2006 Sep 26

PMID 16998752

Citations 6

Authors

Raymond Voltz

Affiliations

Soon will be listed here.

Abstract

Combining clinical and immunological information, a neurological syndrome can now be diagnosed as a "definite" or "possible" paraneoplastic syndrome according to the newly suggested diagnostic criteria of the PNS Euronetwork. Differentiated diagnosis of a paraneoplastic syndrome is essential for differential therapy in patients. According to the response to IVIG therapy, paraneoplastic disorders may be subgrouped in group A, a clinical response is the rule (prototype Lambert-Eaton myasthenic syndrome), and in group B, IVIG may be helpful in single patients and is indicated in specific clinical settings (prototype anti-Hu associated neurological syndromes). The mode of action of IVIG may range from direct anti-idiotype effect to indirect effects on the cellular part of the pathogenesis of paraneoplastic syndromes. Due to the therapeutic relevance, it is therefore important to diagnose a PND as early as possible, and start immunotherapy including IVIG immediately.

Citing Articles

Neuroendocrine carcinoma of the small intestine diagnosed as a result of paraneoplastic neurological syndrome.

Nakazawa K, Hirata Y, Kakimoto K, Miyazaki T, Ota S, Hamamoto H Clin J Gastroenterol. 2023; 16(5):663-667.

PMID: 37434043 DOI: 10.1007/s12328-023-01822-w.

Paraneoplastic neurological syndromes associated with gastric cancer: a case report and review of the literature.

Taketa T, Ohigashi S, Suzuki K, Sudo K, Shiozaki H, Suzuki A Clin J Gastroenterol. 2015; 5(5):355-60.

PMID: 26181075 DOI: 10.1007/s12328-012-0328-z.

Successful Treatment with Methylnaltrexone and IVIG for Paraneoplastic Syndrome-Associated Intestinal Pseudo-Obstruction.

Zhang C, Patel N, Jacobs W, Ullman S, Berzin T, Chuttani R Gastroenterol Hepatol (N Y). 2014; 9(1):48-51.

PMID: 24707235 PMC: 3975979.

Treatment of paraneoplastic cerebellar degeneration.

Greenlee J Curr Treat Options Neurol. 2013; 15(2):185-200.

PMID: 23315179 PMC: 7102346. DOI: 10.1007/s11940-012-0215-4.

Treatment of paraneoplastic neurologic disorders.

Greenlee J Curr Treat Options Neurol. 2010; 12(3):212-30.

PMID: 20842583 DOI: 10.1007/s11940-010-0066-9.

References

Maddison P, Newsom-Davis J . Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2005; (2):CD003279. DOI: 10.1002/14651858.CD003279.pub2. View

Blaes F, Strittmatter M, Merkelbach S, Jost V, Klotz M, Schimrigk K . Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J Neurol. 1999; 246(4):299-303. DOI: 10.1007/s004150050350. View

Voltz R, Gultekin S, Rosenfeld M, Gerstner E, Eichen J, Posner J . A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med. 1999; 340(23):1788-95. DOI: 10.1056/NEJM199906103402303. View

Darnell R, Posner J . Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003; 349(16):1543-54. DOI: 10.1056/NEJMra023009. View

Illa I . IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. J Neurol. 2005; 252 Suppl 1:I14-8. DOI: 10.1007/s00415-005-1104-5. View

Dalakas M . The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol. 2005; 252 Suppl 1:I19-25. DOI: 10.1007/s00415-005-1105-4. View

Muchnik S, Losavio A, Vidal A, Cura L, Mazia C . Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve. 1997; 20(6):674-8. DOI: 10.1002/(sici)1097-4598(199706)20:6<674::aid-mus3>3.0.co;2-5. View

van der Meche F, Schmitz P . A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992; 326(17):1123-9. DOI: 10.1056/NEJM199204233261705. View

Benyahia B, Liblau R, Merle-Beral H, Tourani J, Dalmau J, Delattre J . Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol. 1999; 45(2):162-7. DOI: 10.1002/1531-8249(199902)45:2<162::aid-ana5>3.0.co;2-r. View

10.

Vincent A, Buckley C, Schott J, Baker I, Dewar B, Detert N . Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004; 127(Pt 3):701-12. DOI: 10.1093/brain/awh077. View

11.

Graus F, Delattre J, Antoine J, Dalmau J, Giometto B, Grisold W . Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004; 75(8):1135-40. PMC: 1739186. DOI: 10.1136/jnnp.2003.034447. View

12.

Wolfe G, Barohn R, Foster B, Jackson C, Kissel J, Day J . Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve. 2002; 26(4):549-52. DOI: 10.1002/mus.10224. View

13.

Voltz R . Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol. 2003; 1(5):294-305. DOI: 10.1016/s1474-4422(02)00135-7. View

14.

van der Meche F, van Doorn P . The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders. Muscle Nerve. 1997; 20(2):136-47. DOI: 10.1002/(sici)1097-4598(199702)20:2<136::aid-mus1>3.0.co;2-d. View

15.

Buchwald B, Ahangari R, Weishaupt A, Toyka K . Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins. Muscle Nerve. 2005; 31(4):487-94. DOI: 10.1002/mus.20269. View

16.

Hill C, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A . Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001; 357(9250):96-100. DOI: 10.1016/S0140-6736(00)03540-6. View

17.

Bain P, Motomura M, Newsom-Davis J, Misbah S, Chapel H, Lee M . Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996; 47(3):678-83. DOI: 10.1212/wnl.47.3.678. View

18.

Dalakas M, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B . High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2002; 345(26):1870-6. DOI: 10.1056/NEJMoa01167. View

19.

Voltz R, Albrich W, Nagele A, Schumm F, Wick M, Freiburg A . Paraneoplastic myasthenia gravis: detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor. Neurology. 1997; 49(5):1454-7. DOI: 10.1212/wnl.49.5.1454. View

20.

Voltz R, Albrich W, Hohlfeld R, Nagel D, Wick M, Kirchner T . Anti-titin antibodies are not associated with a specific thymoma histology. J Neurol Neurosurg Psychiatry. 2003; 74(2):282. PMC: 1738272. DOI: 10.1136/jnnp.74.2.282. View